Filing Details
- Accession Number:
- 0001415889-24-027710
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-26 16:15:08
- Reporting Period:
- 2024-11-22
- Accepted Time:
- 2024-11-26 16:15:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1660334 | Verrica Pharmaceuticals Inc. | VRCA | Pharmaceutical Preparations (2834) | 463137900 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709418 | Iii A John Stalfort | C/O Verrica Pharmaceuticals Inc. 44 West Gay Street, Suite 400 West Chester PA 19380 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-22 | 1,123,595 | $0.00 | 1,823,800 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2024-11-26 | 50,000 | $0.00 | 1,873,800 | No | 4 | G | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | G | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Warrants (right to buy) | Acquisiton | 2024-11-22 | 561,797 | $0.00 | 561,797 | $1.07 |
| Common Stock | Series B Warrants (right to buy) | Acquisiton | 2024-11-22 | 561,797 | $0.00 | 561,797 | $1.34 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 561,797 | 2024-11-22 | 2025-11-22 | No | 4 | P | Direct |
| 561,797 | 2024-11-22 | 2029-11-22 | No | 4 | P | Direct |
Footnotes
- The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Billionaire Hedge Funds
